Citations

Clear

511 citation(s) found for "Seth, N".

ALISertib in combination with endocrine therapy in patients with hormone receptor-positive (HR+), HER2-negative (HER2–) recurrent or metastatic breast cancer: The phase 2 ALISCA-Breast1 study.
Advani, Pooja , Braga, Sofía , McCann, Kelly , O'Regan, Ruth M., Manich, C. Saura, Lowenthal, Beth Hillary, Bebchuk, Judith D. , O’Shaughnessy, Joyce , Haddad, Tufia C. , Brufsky, Adam , Giridhar, Karthik V. , Mayer, Erica L. , Saura, Cristina , Wander, Seth Andrew , Bischof, Georg Friedrich, Eli, Lisa D. , Barnett, Brian

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.tps1125 Get It

TPS1125 Background: Despite the many available treatments for patients (pts) with HR+, HER2– recurrent/metastatic breast cancer (MBC), optimal treatment after progression on CDK4/6 inhibitors (CDK4/6i) is unclear. One possible CDK4/6i resistance mechanism is increased expression of Aurora kinase A (AURKA), a key mitosis regulator associated with poor prognosis. Further implicated in CDK 4/6i resistance, high c-Myc or RB1 loss of function (LOF) are associated with transcriptional co-regulation or synthetic lethality, respectively, with AURKA. Alisertib is a highly selective, reversible, ATP-competitive, orally administered, small-molecule AURKA inhibitor with antiproliferative activity in HR+ BC-derived cell lines and BC xenograft models. Models with elevated AURKA or c-Myc expression, or RB1 LOF show greater alisertib sensitivity. Alisertib had activity in phase 1 and 2 trials, including objective response rates (ORRs) of 19.6–20% and median progression-free survival (PFS) of 5.4–5.6 months alone or with fulvestrant in pts with HR+/HER2–, endocrine-resistant MBC. The most common treatment-related grade ≥3 adverse events (AEs) were neutropenia, anemia, and leukopenia. Methods: ALISCA-Breast1 (NCT06369285) is a randomized phase 2 study. Primary objective: to determine the optimal alisertib dose administered with endocrine therapy (ET) based on AEs and serious AEs per CTCAE v5.0 and efficacy (ORR, duration of response, disease-control rate, PFS, overall survival). Secondary objectives: to identify biomarkers of efficacy and alisertib pharmacokinetics (PK). Key inclusion criteria: ≥18 years; ECOG performance status 0 or 1; confirmed HR+, HER2–, recurrent/metastatic breast adenocarcinoma not amenable to curative therapy; available tumor tissue for biomarker analyses; progression on or after ≥2 prior ET lines in recurrent/metastatic setting; prior CDK4/6i with ET in recurrent/metastatic setting. Key exclusion criteria: prior chemotherapy in recurrent/metastatic setting; prior AURKA-specific or pan-Aurora-targeted agents; unstable brain metastases. Eligible pts will be randomized 1:1:1 to alisertib 30 mg, 40 mg, or 50 mg orally twice daily on days 1−3, 8–10, and 15–17 every 28 days, plus physician’s choice of anastrozole, letrozole, exemestane, fulvestrant, or tamoxifen not previously used in recurrent/metastatic setting or progressed upon in adjuvant setting; ≤50 pts will be enrolled per arm in the USA and Europe. All pts will undergo sparse PK sampling. Tumor tissue will be centrally assessed for biomarkers, including RB1, MYC, TP53, ESR1, PI3K/AKT pathway, HER2 and AURKA genomic alterations/expression levels. The study will determine the optimal alisertib dose to combine with ET and may identify biomarker(s) defining pts with the greatest benefit from alisertib-based therapy. Clinical trial information: NCT06369285 .
Feasibility of vaginal tampon versus swab in the collection of vaginal fluid for endometrial cancer testing.
Krakowski, Katelyn, Lemens, Maureen A. , Burger, Kelli N. , Gonser, Anna M. , Kroll, Laura, Narula, Gagandeep, Schroeder, Paige, Hanson, Hallie, Harings, Kathleen, Kielar‐Grevstad, Elle, Gagrat, Bridget Z. , Domanico, Michael J. , Harrington, Shariska P. , Slettedahl, Seth W. , Foote, Patrick H. , Berger, Calise K. , Taylor, William R. , Mahoney, Douglas W. , Kroll, Laura, Narula, Gagandeep, Schroeder, Paige, Kisiel, John B. , Bakkum‐Gamez, Jamie N.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e17617 Get It

e17617 Background: Abnormal uterine bleeding (AUB) is a cardinal symptom of endometrial cancer (EC). However, 90-95% of those with AUB will undergo invasive endometrial sampling with the finding of benign etiology. Our group has identified EC-related methylated DNA markers (MDMs) detectable in vaginal fluid obtained via self-collected tampon with high sensitivity to detect EC. To provide alternative vaginal fluid collection options, we compared total DNA recovery and detection of EC MDMs between tampon and swab collection methods. Methods: Patients ≥45 yrs with AUB or undergoing routine gynecologic care, and patients ≥18 yrs with biopsy-confirmed EC or atypical endometrial hyperplasia (AEH) were prospectively enrolled for paired vaginal fluid biospecimens collection. Participants self-collected vaginal fluid via tampon before provider-collected vaginal fluid sampling via swab immediately prior to clinically indicated endometrial sampling or hysterectomy. Cases (EC/AEH) and benign controls were determined by expert review. DNA was extracted from vaginal fluid. Bisulfite converted DNA was then used in long-probe quantitative amplified signal (LQAS) assays for 10 MDMs and 2 reference markers (RMs). Total DNA recovery using the RMs and detection of EC-specific MDMs were compared across sampling techniques. MDMs were standardized using the log of the ratio of the MDM and RM1. Standardized MDMs were compared between swabs and tampons using median and interquartile range (IQR). Results: A total of 40 eligible participants were evaluated in this study, 20 cases and 20 controls. Median time between tampon and swab collection was 27 hours (range 1-53). DNA quantity as measured using both RM1 and RM2 were comparable between swab and tampon in both cases and controls; MDM detection was also comparable between swab and tampon in both cases and controls (Table 1; 8 representative MDMs shown). Though not powered for sensitivity and specificity estimation, EC-related MDMs appear higher in EC cases vs controls, using either sample type. Conclusions: Sampling vaginal fluid with provider-collected swabs or self-collected tampons are both effective for detection of validated EC MDMs. Studies are ongoing to optimize an MDM panel to detect EC in vaginal fluid. Control Tampon Control Swab Case Tampon Case Swab RM1 3.5 [3.3-3.8] 4.2 [3.8-4.2] 3.6 [3.2-3.9] 4.2 [3.8-4.5] MDM1 0.5 [0.4-0.7] 0.4 [0.2-0.6] 1.3 [0.8-1.8] 1.1 [0.6-1.7] MDM2 1.5 [1.2-1.9] 0.9 [0.7-1.2] 3.2 [2.2-4.7] 2.9 [1.7-4.5] MDM3 0.5 [0.4-0.6] 0.4 [0.3-0.5] 1.5 [0.9-2.3] 1.0 [0.8-2.3] MDM4 0.9 [0.6-1.3] 0.5 [0.4-0.7] 2.3 [1.3-3.7] 1.9 [1.0-3.6] MDM5 1.3 [0.6-1.4] 0.8 [0.6-1.0] 3.3 [2.5-4.1] 3.1 [2.4-3.9] MDM6 1.6 [1.3-2.1] 1.2 [0.8-1.7] 3.3 [2.6-4.3] 3.1 [2.3-4.1] MDM7 1.5 [1.1-1.7] 1.0 [0.4-1.4] 3.5 [2.6-4.1] 3.3 [2.1-3.8] MDM8 0.5 [0.3-0.6] 0.5 [0.4-0.7] 1.8 [1.0-2.7] 1.7 [1.0-2.5] Median (IQR) for RM1 and 8 MDMs by case/control and sampling technique.
Characterizing Disease Severity Through Surgical Recurrence Rates in Idiopathic Subglottic Stenosis
Bowen, Andrew J. , Awadallah, Andrew S. , McCalla, Monet, Roitman, Ariel , Ali, Hawa M. , Leverson, Glen, Khalil, Yousuf H. , Ring, Sydney , Edell, Eric S. , Xie, Katherine , Francis, David O. , Ekbom, Dale C. , Dailey, Seth H. , Bowen, Andrew Jay , Awadallah, Andrew , Ali, Hawa , Edell, Eric, Koster, Matthew, Xie, Katherine Z , Davis, Ruth , Francis, David O , Ekbom, Dale , Dailey, Seth H , Koster, Matthew J. , Bayan, Semirra L.

Mayo Clinic

The Laryngoscope | May 21, 2025 | Volume: 135 | Issue: 10 | Pages: 3766-3773

10.1002/lary.32280 | PMID 40396584 Get It

ABSTRACTObjectiveThere is currently not a marker of disease severity in idiopathic subglottic stenosis (iSGS). Our objective was to characterize iSGS patients' disease severity using endoscopic surgery rates.MethodsThis was a two‐center retrospective analysis of iSGS patients with a minimum of 4 years of follow up following an initial endoscopic procedure (laser wedge excision (LWE) or endoscopic dilation (ED)). Disease severity was classified into Groups A–C, based on whether patients had fewer (Group A), the same number (Group B), or more surgeries (Group C) in years 3–5 compared to years 1 and 2. Disease severity proportions were compared across institutions using chi‐square analysis. Nonparametric testing compared clinical characteristics such as age, BMI, and GERD across severity groups.ResultsThere were 104 patients from institution 1 and 53 patients from institution 2 that were all female and predominantly Caucasian. Both institutions had clinically and statistically similar proportions of patients in Group A (64% vs. 62%), Group B (20% vs. 19%), and Group C (16% vs. 19%) disease (p > 0.05). No clinical characteristic (e.g., age, sex, race, BMI, GERD) was associated with disease severity.ConclusionAcross tertiary care institutions there is a consistent proportion of iSGS patients who either demonstrate nonrecurrent/decelerating (Group A), stable but persistent (Group B), or rapidly recurring disease (Group C). Two‐year surgery rates appear to be an important timepoint for providing expectations to patients on the likelihood of possessing severe disease.Level of Evidence4
An Intervention to Increase Advance Care Planning Among Older Adults With Advanced Cancer
Volandes, Angelo E., Chang, Yuchiao , Paasche‐Orlow, Michael K. , Lindvall, Charlotta , Zupanc, Seth N., Martins-Welch, Diana , Carney, Maria Torroella , Burns, Edith , Itty, Jennifer, Emmert-Tangredi, Kaitlin, Martin, Narda J., Sanghani, Shreya, Tilburt, Jon C. , Davis, Aretha Delight , Garde, Cynthia, El‐Jawahri, Areej , Quintiliani, Lisa M. , Sciacca, Kate, Tulsky, James A. , Lakin, Joshua R. , Zupanc, Sophia N. , Pollak, Kathryn I. , Barry, Michael J. , Goldman, Julie

Mayo Clinic

JAMA Network Open | May 9, 2025 | Volume: 8 | Issue: 5 | Pages: e259150

10.1001/jamanetworkopen.2025.9150 | PMID 40343696 Get It

Importance Many older adults with advanced cancer never communicate goals of care or treatment preferences to their clinicians, raising the risk that care received will not match their values. Scalable models of care may help surmount this barrier. Objective To test whether a combined patient and clinician intervention increased the rate of advance care planning (ACP) documentation in large health care systems. Design, Setting, and Participants This stepped-wedge cluster randomized clinical trial using an open cohort design included patients aged 65 years or older with advanced cancer seen at oncology clinics in 3 health care systems located in the US South, Midwest, and Mid-Atlantic regions from April 1, 2020, to November 30, 2022. Data collection ended in 2024. Intervention The intervention involved delivering brief evidence-based patient-facing video decision aids available in 25 languages as well as goals-of-care communication training to oncology clinicians. Patients in the control period received usual care. Main Outcomes and Measures The primary outcome was ACP documentation, which included any electronic health record documentation of a goals-of-care conversation, palliative care, hospice, or limitation of life-sustaining treatments, identified via a validated natural language processing program. Analysis was performed on an intention-to-treat basis. Results Twenty-nine practices, comprising 13 800 unique eligible patients with a total of 29 357 repeated measurements, were included (mean [SD] age, 74.5 [6.6] years; 52.3% men [15 344 of 29 357 measurements]). The proportion of patients with ACP documentation was greater in the intervention phase compared with the usual care phase (adjusted rate difference, 6.8% [95% CI, 2.8%-10.8%]; P < .001). ACP documentation in the intervention phase occurred among 3980 of 15 754 patients (25.3%) (goals-of-care conversation, 21.4% [3377 of 15 754]; palliative care, 9.6% [1517 of 15 754]; hospice, 5.4% [847 of 15 754]; and limitation of life-sustaining treatments, 7.2% [1128 of 15 754]). In comparison, ACP documentation in the usual care phase occurred among 2834 of 13 603 patients (20.8%) (goals-of-care conversation, 16.8% [2281 of 13 603]; palliative care, 9.5% [1287 of 13 603]; hospice, 5.3% [724 of 13 603]; and limitation of life-sustaining treatments, 8.4% [1149 of 13 603]). Conclusions and Relevance In this stepped-wedge cluster randomized clinical trial for older adults with advanced cancer, a bundled evidence-based decision aid and communication training intervention increased the proportion of older patients with ACP documentation. This approach offers an innovative paradigm with a clinically meaningful increase in ACP documentation, a widely used quality metric that reflects high-quality patient-centered care delivery. Trial Registration ClinicalTrials.gov Identifier: NCT03609177
3D Printed Hollow Microneedles for Dermal and Transdermal Drug Delivery: Design, Fabrication, Application, and Perspective
Ghaznavi, Amirreza , Alavi, Sonia , Hara, Seth A. , Gemeinhart, Richard A. , Xu, Jie , Gemeinhart, Richard A , Xu, Jie , Lin, Yang

Mayo Clinic

Molecular Pharmaceutics | May 5, 2025 | Volume: 22 | Issue: 6 | Pages: 2747-2764

10.1021/acs.molpharmaceut.4c01261 | PMID 40323438 Get It

A Quarterly Multidisciplinary Craniofacial Operative Team Conference to Improve Surgical Outcomes and Adherence to Clinical Pathways: Does it Work?
Grove, Austin M. , Kirsch, Hannah M., Hanley, Seth P., Bristol, Ruth E., Kurnik, Nicole M. , Singh, Davinder J. , Singh, Davinder J , Grove, Austin , Sitzman, Thomas J.

Mayo Clinic

Journal of Craniofacial Surgery | May 5, 2025 | Volume: 36 | Issue: 7 | Pages: 2306-2310

10.1097/scs.0000000000011468 | PMID 40323582 Get It

Craniofacial surgery requires a multidisciplinary care approach in the perioperative period. In an effort to guide clinical decision making and standardize care, many institutions have implemented craniofacial surgical pathways, describing numerous variables to monitor and specific actions that must be completed by each involved discipline in the perioperative period. Adherence to these pathways can be challenging given the complexity of the protocol and the multiple disciplines involved. In an effort to improve adherence to our institution’s perioperative pathway, the authors implemented a quarterly, multidisciplinary craniofacial operative team meeting to review the pathway and improve the quality of care. The authors report results from a retrospective review of craniosynostosis suturectomy operations at a single site in the 2 years before and 2 years after the start of our team meeting to review perioperative care. A total of 141 operations were included (70 before the meeting and 71 after). Perioperative outcomes and adherence to our surgical pathway were compared. Following the start of our team meetings, there was a significant decrease in the time under anesthesia, patients requiring blood transfusion, and total hospital length of stay ( P <0.05). There was also improved adherence to the craniofacial pathway, with significantly more operations applying peripheral nerve blocks to all locations specified in our pathway with the proper drug contents ( P <0.05). Our findings suggest that craniofacial operative team meetings with a goal of reviewing the surgical pathway and discussing improvements in care plans with all involved providers can significantly improve adherence to operative pathways and surgical outcomes.
Clinical phenotypes among patients with familial forms of Chiari malformation type 1
Mekbib, Kedous Y. , Allington, Garrett , Zhao, Shujuan, Fortes, Carla, Shohfi, John, Nelson‐Williams, Carol , Butler, William E. , Alper, Seth L. , Jackson, Eric M., Muñoz, William , Mehta, Neel H. , Fan, Baojian , DeSpenza, Tyrone , Kahle, Kristopher T.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | May 2, 2025 | Volume: 36 | Issue: 1 | Pages: 109-118

10.3171/2025.1.peds24187 | PMID 40315599 Get It

OBJECTIVE Chiari malformation type 1 (CM1) is the most common neurological disorder of the craniocervical junction. CM1 is characterized by cerebellar tonsillar herniation below the foramen magnum, causing CSF obstruction and neural compression. Patients with CM1 suffer from highly variable symptoms, progression, comorbidities, and outcomes, partly due to poor understanding of CM1 pathogenesis. In this paper, the authors present the only familial CM1 cohort study to statistically assess intrafamilial clinical phenotypes to date. METHODS Comprehensive medical, surgical, and family histories and neuroimaging were collected from families with multiple CM1-affected family members. Univariate analysis was performed for each symptom, comorbidity, or surgery to compare observed versus expected frequencies of affected patients with another CM1-affected family member with the same clinical characteristic. RESULTS Twenty-four new familial CM1 cases (totaling 57 patients with CM1) are presented. Intrafamilial similarities were identified for age of onset, symptoms such as headaches (p = 0.007) and neck pain (p = 0.018), neurological comorbidities such as syringomyelia (p = 0.003) and hydrocephalus (p = 0.0001), neurodevelopmental conditions such as dyslexia (p < 0.0001), and connective tissue disorders (CTDs) such as Ehlers-Danlos syndrome (p < 0.0001). CONCLUSIONS These results suggest that CM1 and its associated clinical phenotypes, including age of onset, clinical symptoms, neurological comorbidities, neurodevelopmental conditions, and CTDs, are genetically influenced. Whole-exome sequencing of CM1 patient-parent trios has the potential to identify the genetic determinants of CM1, with implications for neurosurgical management.
Acute Respiratory Distress and Oxygen Refractory Hypoxemia in a Term Newborn
Jenson, Anders C., Gregory, Seth W. , Penfold, Michael , Jenson, Anders C. , Penfold, Michael P , Jenson, Anders , Taggart, Nathaniel W. , Penfold, Michael P.

Mayo Clinic

Pediatrics in Review | May 1, 2025 | Volume: 46 | Issue: 5 | Pages: 267-272

10.1542/pir.2023-006076 | PMID 40306711 Get It

A multicenter study of the real-world effectiveness and safety of risankizumab in Crohn’s disease
Johnson, Amanda M. , Askar, Manar, Belani, Seema, Xu, Anthony , Kassmeyer, Blake , Said, Hyder , Santiago-Castro, Michael, Devi, Jalpa , Huang, Katherine , Jaiprada, Fnu, Seth, Nickhil, Dulaney, David , Fenster, Marc, Shukla, Richa, Yarur, Andrés , Santiago-Castro, Michael , Devi, Jalpa , Bishu, Shrinivas , Ungaro, Ryan , Deepak, Parakkal , Yarur, Andres J , Khan, Abdul Wali , Seth, Nickhil, Loftus, Edward V. , Patel, Anish A , Bishu, Shrinivas , Ungaro, Ryan C. , Shukla, Richa, Deepak, Parakkal

Mayo Clinic

Journal of Crohn's and Colitis | April 18, 2025 | Volume: 19 | Issue: 5 | Pages: No page available

10.1093/ecco-jcc/jjaf070 | PMID 40289770 Get It

Abstract Background We aimed to evaluate the effectiveness and safety of risankizumab (RZB) for Crohn’s disease (CD) in routine clinical practice. Methods We performed a retrospective review of a multicenter consortium of CD patients treated with RZB. Co-primary outcomes were week 12 clinical remission (Harvey Bradshaw Index [HBI] score of ≤4 or physician global assessment in those without HBI or with ileostomy) and 6-month endoscopic remission (Simplified Endoscopic Mucosal Assessment for Crohn’s Disease of 0-1 or absence of ulcers). Secondary outcomes included steroid-free clinical remission, clinical response, radiographic response, cumulative clinical and endoscopic remission rates at 6 and 12 months, and adverse events. Results A total of 309 patients were included (median disease duration 14 years [IQR, 6-24]; median follow-up 7.1 months [IQR, 4.1-10.3]). Most patients (85.8%) were advanced therapy (AT)-exposed, and 169 (54.7%) had prior ustekinumab (UST) exposure. Week 12 clinical remission rates were 49.7% (98/197) overall, and 44.2% (50/113) vs 57.1% (48/84) in UST-exposed vs naïve patients (P = .073). Among those with active disease on baseline endoscopy (n = 122) who had an available follow-up at 6 months, 52.4% (22/42) achieved endoscopic remission. Cumulative rates of clinical and endoscopic remission at 12 months were 65.0% and 49.5%, respectively. Cumulative 12-month endoscopic remission was 33.9% (19/56) in UST-exposed and 68.1% (32/47) in UST-naïve patients (P &lt; .001). Risankizumab was well-tolerated with no new safety signals identified. Conclusions In this large multicenter cohort of patients with CD, RZB was well-tolerated and effective in achieving favorable clinical and endoscopic outcomes in both AT-exposed and naïve populations, including those with exposure to UST.
Surgical Recurrence Across Endoscopic Surgical Techniques in Idiopathic Subglottic Stenosis
Bowen, Andrew J. , Awadallah, Andrew S. , Ali, Hawa M. , McCalla, Monet, Roitman, Ariel , Leverson, Glen, Khalil, Yousuf H. , Ring, Sydney , Edell, Eric S. , Xie, Katherine , Francis, David O. , Dailey, Seth H. , Ekbom, Dale C. , Bowen, Andrew Jay , Ali, Hawa , Edell, Eric, Koster, Matthew, Xie, Katherine Z , Davis, Ruth , Francis, David O , Dailey, Seth H , Ekbom, Dale , Awadallah, Andrew , Bayan, Semirra L. , Koster, Matthew J.

Mayo Clinic

The Laryngoscope | April 15, 2025 | Volume: 135 | Issue: 9 | Pages: 3280-3286

10.1002/lary.32181 | PMID 40231755 Get It

ABSTRACTObjectiveWhile endoscopic laser wedge excision (LWE) for iSGS demonstrated lower surgical recurrence rates compared to endoscopic dilation (ED), ED remains the primary technique employed. Additionally, serial intralesional steroid injections (SILSIs) also demonstrate benefits in controlling disease. We aimed to compare surgical recurrence rates following ED, ED + SILSI, and LWE following a patient's first operation.MethodsThis was a two‐center retrospective analysis of iSGS patients who underwent either ED, ED + SILSI, or LWE. Patients were followed to their last follow‐up date or reoperation. Kaplan–Meier analysis and Cox proportional hazards were used to evaluate the recurrence times across the different surgical groups with additional stratification by age, compliance to medical adjuvant therapy, and percentage of stenosis rated at reoperation.ResultsA total of 126 patients from Institution 1 underwent LWE, while at Institution 2, ED and ED + SILSI were performed on 32 and 23 patients, respectively. One‐year recurrence estimates were 9%, 53%, and 0% for LWE, ED, and ED + SILSI, respectively, while 5‐year recurrence estimates were 45%, 90%, and 19%, respectively. Adjusted Cox‐proportional hazard ratios demonstrated a greater risk of surgical recurrence with ED compared to LWE (2.25; 95% confidence interval [CI]: 1.31–3.88) and no difference between ED + SILSI and LWE (0.84; 95% CI: 0.32–2.25).ConclusionLWE demonstrates reduced recurrence times compared to ED when controlling for surgery number, age, triple therapy compliance, and percentage of stenosis at reoperation. The application of postoperative SILSI appears to similarly reduce recurrence rates comparable to LWE and warrants further investigation.